Paper26229727
Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.
Coyne CP and 4 others. J Cancer Ther, 2011. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium. Papers, record 26229727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26229727
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| T35 OD010432 | NIH HHS | United States | T35OD010432 | PubMed and NIH |
Source NIH RePORTER
References88
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15458769 | The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? | Pharmacol Res | 2004 | https://conductscience.org/library/papers/15458769 | PubMed |
| 2 | 19101136 | In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with a quartz crystal microbalance. | Biosens Bioelectron | 2009 | https://conductscience.org/library/papers/19101136 | PubMed |
| 3 | 12459020 | Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. | J Med Chem | 2002 | https://conductscience.org/library/papers/12459020 | PubMed |
| 4 | 17131338 | The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXO-EMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. | Int J Cancer | 2007 | https://conductscience.org/library/papers/17131338 | PubMed |
| 5 | 8564396 | Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro. | Bioorg Med Chem | 1995 | https://conductscience.org/library/papers/8564396 | PubMed |
| 6 | 17702197 | Anthracycline-based combined chemotherapy in the mouse model. | Eur J Drug Metab Pharmacokinet | 2007 | https://conductscience.org/library/papers/17702197 | PubMed |
| 7 | 2515870 | Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. | Mol Biother | 1989 | https://conductscience.org/library/papers/2515870 | PubMed |
| 8 | 15073137 | Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15073137 | PubMed |
| 9 | 15621674 | Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. | J Drug Target | 2004 | https://conductscience.org/library/papers/15621674 | PubMed |
| 10 | 8327892 | Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. | Science | 1993 | https://conductscience.org/library/papers/8327892 | PubMed |
| 11 | 10589780 | Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin. | Clin Cancer Res | 1999 | https://conductscience.org/library/papers/10589780 | PubMed |
| 12 | 11821453 | Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. | J Clin Oncol | 2002 | https://conductscience.org/library/papers/11821453 | PubMed |
| 13 | 19253922 | Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. | Chembiochem | 2009 | https://conductscience.org/library/papers/19253922 | PubMed |
| 14 | 10632061 | Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. | Bioorg Med Chem | 1999 | https://conductscience.org/library/papers/10632061 | PubMed |
| 15 | 15567293 | A novel method for coupling doxorubicin to lactosaminated human albumin by an acid sensitive hydrazone bond: synthesis, characterization and preliminary biological properties of the conjugate. | Eur J Pharm Sci | 2004 | https://conductscience.org/library/papers/15567293 | PubMed |
| 16 | 16611663 | Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug. | Jpn J Clin Oncol | 2006 | https://conductscience.org/library/papers/16611663 | PubMed |
| 17 | 1382845 | Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. | Cancer Res | 1992 | https://conductscience.org/library/papers/1382845 | PubMed |
| 18 | 15382077 | Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells. | Int J Cancer | 2004 | https://conductscience.org/library/papers/15382077 | PubMed |
| 19 | 9870393 | Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis. | Electrophoresis | 1998 | https://conductscience.org/library/papers/9870393 | PubMed |
| 20 | 10928049 | Effect of selenium in combination with Adriamycin or Taxol on several different cancer cells. | Anticancer Res | 2000 | https://conductscience.org/library/papers/10928049 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 27574398 | Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). | Drug Des Devel Ther | 2016 | https://conductscience.org/library/papers/27574398 | PubMed |
| 27561602 | Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). | Chem Biol Drug Des | 2017 | https://conductscience.org/library/papers/27561602 | PubMed |
| 26613088 | Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549). | J Pharm Drug Deliv Res | 2015 | https://conductscience.org/library/papers/26613088 | PubMed |
| 26251840 | Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. | J Clin Exp Oncol | 2013 | https://conductscience.org/library/papers/26251840 | PubMed |
| 26225219 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3). | Med Chem (Los Angeles) | 2013 | https://conductscience.org/library/papers/26225219 | PubMed |
| 26225216 | Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. | J Cancer Ther | 2012 | https://conductscience.org/library/papers/26225216 | PubMed |
| 26225190 | Influence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and Alternative Tubulin/Microtubule Inhibitors on the Cytotoxic Anti-Neoplastic Potency of Epirubicin-(C3-amide)-Anti-HER2/neu Synthesized Utilizing a UV-Photoactivated Anthracycline Intermediate. | Cancer Clin Oncol | 2012 | https://conductscience.org/library/papers/26225190 | PubMed |
| 25844392 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. | J Cancer Res Ther Oncol | 2014 | https://conductscience.org/library/papers/25844392 | PubMed |
| 25821636 | Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. | J Cancer Ther | 2015 | https://conductscience.org/library/papers/25821636 | PubMed |
| 22191802 | Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate. | Cancer Biother Radiopharm | 2012 | https://conductscience.org/library/papers/22191802 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26229727
GET https://conductscience.org/api/papers/v1/26229727/references?page=2